Intervention

Radium Ra 223 Dichloride

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting1

Common conditions17

Lead sponsors shown6

Clinical trials

9 shown

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate CancerNCT04489719 · 2021-04-16

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyNCT04071236 · 2020-10-14

ACTIVE_NOT_RECRUITING

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the BonesNCT04090398 · 2020-08-04

ACTIVE_NOT_RECRUITING

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisNCT03317392 · 2019-02-04

ACTIVE_NOT_RECRUITING

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate CancerNCT03344211 · 2018-11-21

ACTIVE_NOT_RECRUITING

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate CancerNCT03361735 · 2018-08-29

ACTIVE_NOT_RECRUITING

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to BoneNCT03304418 · 2018-02-27

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)NCT03076203 · 2017-09-22

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate CancerNCT02199197 · 2014-06-25

Common conditions

Castration-Resistant Prostate Carcinoma3 Metastatic Malignant Neoplasm in the Bone3 Stage IVB Prostate Cancer AJCC v83 Anatomic Stage IV Breast Cancer AJCC v81 Hormone-refractory Prostate Cancer1 Metastatic Castration-Resistant Prostate Carcinoma1 Metastatic HER2-Negative Breast Carcinoma1 Metastatic Malignant Neoplasm in the Lymph Nodes1 Metastatic Prostate Adenocarcinoma1 Metastatic Prostate Carcinoma1 Prostate Adenocarcinoma1 Prostate Cancer1 Prostate Cancer Metastatic to Bone1 Prostate Carcinoma Metastatic in the Bone1 Prostate Carcinoma Metastatic to the Bone1 Stage IV Prostate Adenocarcinoma1 Stage IV Prostate Cancer1

Leading sponsors

National Cancer Institute (NCI)3 University of Utah2 City of Hope Medical Center1 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1 University of Southern California1 University of Washington1

Trial status mix

ACTIVE_NOT_RECRUITING5

COMPLETED3

RECRUITING1

Phase mix

PHASE27

PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.